A Study of RO5212054 (PLX3603) in Participants With BRAF V600-Mutated Advanced Solid Tumors
NCT01143753
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
45
Enrollment
INDUSTRY
Sponsor class
Conditions
Neoplasms
Interventions
DRUG:
RO5212054
Sponsor
Hoffmann-La Roche